🇺🇸 FDA
Pipeline program

Iclepertin

1346-0014

Phase 3 small_molecule terminated

Quick answer

Iclepertin for Schizophrenia is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 2 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim
Indication
Schizophrenia
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials